The more you find out on PCa, the more you we see there are alot half way decent generalizations, but there are enough exclusions and exceptions to the rules...that you cannot define this easily. The rate of progression or change depends more on the genetic factors, ploidy types, variant types....that can even trump Gleason score values. Patients with identical Gleason scores and even volumes of PCa...can have very different results and longevity even, this is written about
even in Paact Newsletter recently 'Molecular Pathology' by Dr. Doug Chinn...photos with stains shown along with the commentaries. His conclusion is the disease is more individualized than you might realize. There are many genetic factors that could have caused your PCa...they can now identify alot of them, not all of them yet....some of those Dr. Bonkhoff/Dr. Strum have targeted therapies upon treatments for certain genetic risks or issues and have started the paved road towards this new vista in conquering PCa and they were doing so years ago...ahead of the curve.
You can read his info on line at www.paactusa.org go to pages 9-10-11 for the Chinn article. The whole newsletter is better than ever. Dr. Bahn has a new guideline for doing Active Survelliance and it is very complete and you probably never knew all the parameters he would say is righteous for A.S. (worth reading).
Logo- there are cases of PCa with no doubling times or small increases and yet could even have mets happening, some PCa's (rarer versions) may not give off much Psa to measure. This is why a wise onco-doc should monitor the patient, other marker tests can catch things the Psa alone can miss.
Post Edited (zufus) : 4/11/2011 5:30:30 AM (GMT-6)